Composition for collecting and preserving placental stem cells and methods of using the composition

Patent metadata

Field	Value
Publication number	US-9725694-B2
Application number	US-84676510-A
Country	US
Kind code	B2
Filing date	Jul 29, 2010
Priority date	Dec 29, 2005
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.

First claim

What is claimed is:

1. A method of isolating stem cells, the method comprising contacting said stem cells with a solution comprising a caspase inhibitor, a JNK inhibitor, a protease, and either pyrrolidine dithiocarbamate or clonazepam,
wherein the JNK inhibitor is an inhibitor of apoptosis, said JNK inhibitor represented by the structure

wherein:
A is a direct bond, —(CH 2 ) a —, —(CH 2 ) b CH═CH(CH 2 ) c —, or —(CH 2 ) b C≡C(CH 2 ) c —;
R 1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R 3 ;
R 2 is —R 3 , —R 4 , —(CH 2 ) b C(═O)R 5 , —(CH 2 ) b C(═O)OR 5 , —(CH 2 ) b C(═O)NR 5 R 6 ,
—(CH 2 ) b C(═O)NR 5 (CH 2 ) c C(═O)R 6 , —(CH 2 ) b NR 5 C(═O)R 6 ,
—(CH 2 ) b NR 5 C(═O)NR 6 R 7 , —(CH 2 ) b NR 5 R 6 , —(CH 2 ) b OR 5 ,
—(CH 2 ) b SO d R 5 or —(CH 2 ) b SO 2 NR 5 R 6 ;
a is 1, 2, 3, 4, 5 or 6;
b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;
d is at each occurrence 0, 1 or 2;
R 3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, —C(═O)OR 8 , —OC(═O)R 8 , —C(═O)NR 8 R 9 , —C(═O)NR 8 OR 9 , —SO 2 NR 8 R 9 , —NR 8 SO 2 R 9 , —CN, —NO 2 , —NR 8 R 9 , —NR 8 C(═O)R 9 , —NR 8 C(═O)(CH 2 ) b OR 9 , —NR 8 C(═O)(CH 2 ) b R 9 , —O(CH 2 ) b NR 8 R 9 , or heterocycle fused to phenyl;
R 4 is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently selected from R 3 , or R 4 is halogen or hydroxy;
R 5 , R 6 and R 7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R 5 , R 6 and R 7 are optionally substituted with one to four substituents independently selected from R 3 ; and
R 8 and R 9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R 8 and R 9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R 8 , R 9 , and R 8 and R 9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R 3 ;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof;
and wherein said method of isolating further comprises isolating the stem cells subsequent to said contacting step; wherein said stem cells are isolated from a mammalian placenta, and said contacting is performed during perfusion of said mammalian placenta with a perfusion solution comprising said caspase inhibitor, said JNK inhibitor, said protease, and said pyrrolidine dithiocarbamate or clonazepam.

2. The method of claim 1 , wherein the INK inhibitor is 3-(4-fluoro-phenyl)-1H-indazole-5-carboxylic acid amide.

3. The method of claim 1 , additionally comprising contacting said stem cells with an oxygen-carrying perfluorocarbon.

4. The method of claim 1 , wherein said solution is a saline solution.

5. The method of claim 1 , wherein said solution additionally comprises hydroxyethyl starch, lactobionic anion and raffinose.

6. The method of claim 1 , wherein said solution comprises UW solution.

7. The method of claim 1 , wherein said perfusion is performed by passing said perfusion solution into one or both of the umbilical artery and umbilical vein of said placenta.

8. The method of claim 1 , wherein said perfusion solution comprises 0.9% NaCl solution or phosphate buffered saline.

9. The method of claim 1 , wherein said perfusion uses from about 100 mL to about 10,000 mL of said perfusion solution.

10. The method of claim 1 , said method comprising isolating said stem cells, wherein said stem cells are exposed to a hypoxic condition for less than 24 hours during said isolation, wherein a hypoxic condition is a concentration of oxygen that is less than normal blood oxygen concentration.

11. The method of claim 1 , additionally comprising contacting the stem cells with an amino-substituted isoindoline.

12. The method of claim 11 , wherein said amino-substituted isoindoline is a compound represented by the structure

wherein:
one of X and Y is C═O and the other is CH 2 or C═O;
R is H or CH 2 OCOR′;
(i) each of R 1 , R 2 , R 3 , or R 4 , independently of the others, is halo, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms or (ii) one of R 1 , R 2 , R 3 , or R 4 is nitro or —NHR 5 and the remaining of R 1 , R 2 , R 3 , or R 4 are hydrogen;
R 5 is hydrogen or alkyl of 1 to 8 carbons;
R 6 is hydrogen, alkyl of 1 to 8 carbon atoms, benzo, chloro, or fluoro;
R′ is R 7 —CHR 10 —N(R 8 R 9 );
R 7 is m-phenylene or p-phenylene or —(C n H 2n )— in which n has a value of 0 to 4;
each of R 8 and R 9 taken independently of the other is hydrogen or alkyl of 1 to 8 carbon atoms, or R 8 and R 9 taken together are tetramethylene, pentamethylene, hexamethylene, or —CH 2 CH 2 X 1 CH 2 CH 2 — in which X 1 is —O—, —S—, or —NH—;
R 10 is hydrogen, alkyl of to 8 carbon atoms, or phenyl; and
* represents a chiral-carbon center;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof.

13. The method of claim 11 , wherein said substituted isoindoline is 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione, or 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione.

14. The method of claim 1 , wherein said solution additionally comprises a vasodilator.

15. The method of claim 14 , wherein said vasodilator is atrial natriuretic peptide (ANP), adrenocorticotropin, corticotropin-releasing hormone, sodium nitroprusside, hydralazine, adenosine triphosphate, adenosine, indomethacin or magnesium sulfate.

16. The method of claim 1 , wherein said stem cells are CD34+ stem cells.

17. The method of claim 1 , wherein said stem cells are tissue culture plastic-adherent CD34 − , CD10 + , CD105 + , CD200 + placental stem cells.

18. The method of claim 1 , wherein said solution is culture medium.

Assignees

• Edinger James W
• Heidaran Mohammad
• Hofgartner Wolfgang
• Anthrogenesis Corp

Inventors

• Edinger James W
• Heidaran Mohammad
• Hofgartner Wolfgang

Classifications

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• C12N5/0605 Primary

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• C12N2501/48

  Regulators of apoptosis · CPC title

• C12N5/0607 Primary

  Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696) · CPC title

• C12N5/00

  Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00) · CPC title